U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT06904547) titled 'Resistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCLC' on March 21.
Brief Summary: This is a prospective, multicenter, non-interventional, single-arm, real-world study planned to be conducted in China, aimed at exploring the resistance mechanisms of first-line lorlatinib treatment in patients with ALK-positive locally advanced or metastatic NSCLC, as well as the efficacy and safety of sequential treatments following lorlatinib resistance in the real-world setting.
Study Start Date: April 20
Study Type: OBSERVATIONAL
Condition:
First-Line Lorlatinib
Intervention:
OTHER: ...